Cargando…

Budget Impact Analysis of CAR T-cell Therapy for Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in Germany

The aim was to assess the incremental costs of chimeric antigen receptor (CAR) T-cell therapy (axicabtagene ciloleucel, tisagenlecleucel) compared with standard of care in adult patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) from the German third-party payer perspecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Skalt, Daniela, Moertl, Bernhard, von Bergwelt-Baildon, Michael, Schmidt, Christian, Schoel, Wolfgang, Bücklein, Veit, Weiglein, Tobias, Dreyling, Martin, Berger, Karin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9257301/
https://www.ncbi.nlm.nih.gov/pubmed/35813101
http://dx.doi.org/10.1097/HS9.0000000000000736
_version_ 1784741315973480448
author Skalt, Daniela
Moertl, Bernhard
von Bergwelt-Baildon, Michael
Schmidt, Christian
Schoel, Wolfgang
Bücklein, Veit
Weiglein, Tobias
Dreyling, Martin
Berger, Karin
author_facet Skalt, Daniela
Moertl, Bernhard
von Bergwelt-Baildon, Michael
Schmidt, Christian
Schoel, Wolfgang
Bücklein, Veit
Weiglein, Tobias
Dreyling, Martin
Berger, Karin
author_sort Skalt, Daniela
collection PubMed
description The aim was to assess the incremental costs of chimeric antigen receptor (CAR) T-cell therapy (axicabtagene ciloleucel, tisagenlecleucel) compared with standard of care in adult patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) from the German third-party payer perspective. A budget impact model was established over a 6-year period. Estimation of the third-line population: partitioned survival model based on outcome data from peer-reviewed literature, a top-down approach based on population forecasts, and age-standardized incidences. Cost data were derived from the controlling department of a tertiary hospital and a German cost-of-illness study. In the scenario analysis, the budget impact of treating second-line DLBCL patients was calculated. One-way deterministic sensitivity analyses were conducted to test the robustness of the model. For the period 2021-2026, 788-867 (minimum population, min) and 1,068-1,177 (maximum population, max) adult third-line r/r DLBCL patients were estimated. The budget impact ranged from €39,419,562; €53,426,514 (min; max) in year 0 to €122,104,097; €165,763,001 (min; max) in year 5. The scenario analysis resulted in a budget impact of €65,987,823; €89,558,611 (min; max) and €204,485,031; €277,567,601 (min; max) for years 0 and 5, respectively. This budget impact analysis showed a significant but reasonable financial burden associated with CAR T-cell therapy for a limited number of patients requiring individualized care. Further, this study presents challenges and future needs in data acquisition associated with cost analysis in personalized medicine. For comprehensive economic discussions, complementary cost-effectiveness analyses are required to determine the value of innovative therapies for r/r DLBCL.
format Online
Article
Text
id pubmed-9257301
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-92573012022-07-07 Budget Impact Analysis of CAR T-cell Therapy for Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in Germany Skalt, Daniela Moertl, Bernhard von Bergwelt-Baildon, Michael Schmidt, Christian Schoel, Wolfgang Bücklein, Veit Weiglein, Tobias Dreyling, Martin Berger, Karin Hemasphere Article The aim was to assess the incremental costs of chimeric antigen receptor (CAR) T-cell therapy (axicabtagene ciloleucel, tisagenlecleucel) compared with standard of care in adult patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) from the German third-party payer perspective. A budget impact model was established over a 6-year period. Estimation of the third-line population: partitioned survival model based on outcome data from peer-reviewed literature, a top-down approach based on population forecasts, and age-standardized incidences. Cost data were derived from the controlling department of a tertiary hospital and a German cost-of-illness study. In the scenario analysis, the budget impact of treating second-line DLBCL patients was calculated. One-way deterministic sensitivity analyses were conducted to test the robustness of the model. For the period 2021-2026, 788-867 (minimum population, min) and 1,068-1,177 (maximum population, max) adult third-line r/r DLBCL patients were estimated. The budget impact ranged from €39,419,562; €53,426,514 (min; max) in year 0 to €122,104,097; €165,763,001 (min; max) in year 5. The scenario analysis resulted in a budget impact of €65,987,823; €89,558,611 (min; max) and €204,485,031; €277,567,601 (min; max) for years 0 and 5, respectively. This budget impact analysis showed a significant but reasonable financial burden associated with CAR T-cell therapy for a limited number of patients requiring individualized care. Further, this study presents challenges and future needs in data acquisition associated with cost analysis in personalized medicine. For comprehensive economic discussions, complementary cost-effectiveness analyses are required to determine the value of innovative therapies for r/r DLBCL. Lippincott Williams & Wilkins 2022-07-04 /pmc/articles/PMC9257301/ /pubmed/35813101 http://dx.doi.org/10.1097/HS9.0000000000000736 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Article
Skalt, Daniela
Moertl, Bernhard
von Bergwelt-Baildon, Michael
Schmidt, Christian
Schoel, Wolfgang
Bücklein, Veit
Weiglein, Tobias
Dreyling, Martin
Berger, Karin
Budget Impact Analysis of CAR T-cell Therapy for Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in Germany
title Budget Impact Analysis of CAR T-cell Therapy for Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in Germany
title_full Budget Impact Analysis of CAR T-cell Therapy for Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in Germany
title_fullStr Budget Impact Analysis of CAR T-cell Therapy for Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in Germany
title_full_unstemmed Budget Impact Analysis of CAR T-cell Therapy for Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in Germany
title_short Budget Impact Analysis of CAR T-cell Therapy for Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in Germany
title_sort budget impact analysis of car t-cell therapy for adult patients with relapsed or refractory diffuse large b-cell lymphoma in germany
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9257301/
https://www.ncbi.nlm.nih.gov/pubmed/35813101
http://dx.doi.org/10.1097/HS9.0000000000000736
work_keys_str_mv AT skaltdaniela budgetimpactanalysisofcartcelltherapyforadultpatientswithrelapsedorrefractorydiffuselargebcelllymphomaingermany
AT moertlbernhard budgetimpactanalysisofcartcelltherapyforadultpatientswithrelapsedorrefractorydiffuselargebcelllymphomaingermany
AT vonbergweltbaildonmichael budgetimpactanalysisofcartcelltherapyforadultpatientswithrelapsedorrefractorydiffuselargebcelllymphomaingermany
AT schmidtchristian budgetimpactanalysisofcartcelltherapyforadultpatientswithrelapsedorrefractorydiffuselargebcelllymphomaingermany
AT schoelwolfgang budgetimpactanalysisofcartcelltherapyforadultpatientswithrelapsedorrefractorydiffuselargebcelllymphomaingermany
AT buckleinveit budgetimpactanalysisofcartcelltherapyforadultpatientswithrelapsedorrefractorydiffuselargebcelllymphomaingermany
AT weigleintobias budgetimpactanalysisofcartcelltherapyforadultpatientswithrelapsedorrefractorydiffuselargebcelllymphomaingermany
AT dreylingmartin budgetimpactanalysisofcartcelltherapyforadultpatientswithrelapsedorrefractorydiffuselargebcelllymphomaingermany
AT bergerkarin budgetimpactanalysisofcartcelltherapyforadultpatientswithrelapsedorrefractorydiffuselargebcelllymphomaingermany